One-year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicenter real-world study from Italy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
One-year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicenter real-world study from Italy
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume -, Issue -, Pages -
Publisher
Informa UK Limited
Online
2021-09-15
DOI
10.1080/14712598.2021.1981855
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry
- (2021) María Chaparro et al. Journal of Crohns & Colitis
- First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
- (2020) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis
- (2020) Margaux Welty et al. CURRENT MEDICAL RESEARCH AND OPINION
- Difference in treatment outcomes between clinical trials and “real-life” clinical practice: ustekinumab in ulcerative colitis
- (2020) Daniela Pugliese et al. United European Gastroenterology Journal
- Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study
- (2020) Aurélien Amiot et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Lack of evidence for the use of ustekinumab for acute severe ulcerative colitis
- (2020) Jonathan P. Segal et al. United European Gastroenterology Journal
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis
- (2019) Thomas Ochsenkühn et al. United European Gastroenterology Journal
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis
- (2008) James D. Lewis et al. INFLAMMATORY BOWEL DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More